Michael Roppolo, MD
Nephrology · Baton Rouge, LANPI 1639172687
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $9,202 of the $12,801 with a category attached, or 71.9%. 27 manufacturers reported payments, led by Fresenius USA Marketing, Inc. at 46.3% of the total. 2025 is the largest year on record at $5,065, 6.4 times the $792 reported in 2019. Among nephrology clinicians in LA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 380 payments — averaging $33.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Fresenius USA Marketing, Inc.$6K
- AstraZeneca$1K
- Akebia Therapeutics Inc$1K
- Vifor Pharma, Inc.$919
- Mallinckrodt Hospital Products Inc.$383
- Otsuka America Pharmaceutical, Inc.$362
- plus $3K from 21 others
Across 132 payments — averaging $3287.55 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- CSL Behring$242K
- Akebia Therapeutics Inc$44K
- Boehringer Ingelheim$43K
- Biogen$39K
- Bayer$30K
- AstraZeneca$12K
- plus $24K from 4 others
What the payments were for
- Consulting fees$2,40019%
- Travel & lodging$1,0708%
- Food & beverage$9,20272%
- Education$1301%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Fresenius USA Marketing, Inc. | 102 | $5,933 |
| AstraZeneca(2 entities) | 60 | $1,313 |
| Akebia Therapeutics Inc | 49 | $1,123 |
| Vifor Pharma, Inc. | 50 | $919 |
| Mallinckrodt Hospital Products Inc. | 10 | $383 |
| Otsuka America Pharmaceutical, Inc. | 15 | $362 |
| Medtronic | 7 | $359 |
| Bayer | 17 | $358 |
| Amgen(2 entities) | 16 | $306 |
| Novartis | 9 | $299 |
| Baxter Healthcare | 2 | $206 |
| Aurinia Pharma U.S., Inc. | 4 | $177 |
| Sanofi | 2 | $152 |
| OPKO Pharmaceuticals, LLC | 8 | $138 |
| GSK | 3 | $133 |
| Nxstage Medical, Inc. | 2 | $101 |
| Boehringer Ingelheim | 6 | $100 |
| W. L. Gore & Associates, Inc. | 1 | $67 |
| Calliditas Therapeutics US Inc. | 3 | $64 |
| Abiomed | 1 | $60 |
| Daiichi Sankyo Inc. | 2 | $56 |
| Ultragenyx Pharmaceutical Inc. | 3 | $54 |
| ANI Pharmaceuticals, Inc. | 3 | $52 |
| Novo Nordisk | 2 | $32 |
| Idorsia Pharmaceuticals US Inc | 1 | $20 |
| Lilly USA, LLC | 1 | $18 |
| Veloxis Pharmaceuticals, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$12,801 in reported general payments places this provider in the 90th percentile of 206 nephrology providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 113 | $81,136 |
| JardianceEmpagliflozin | 95 | $73,959 |
| ProcritEpoetin Alfa | 42 | $56,616 |
| AuryxiaFerric Citrate | 18 | $13,594 |
| VeltassaPatiromer Calcium Sorbitex | 13 | $11,822 |
| Cinacalcet Hcl | 23 | $4,951 |
| Losartan Potassium | 156 | $1,249 |
| Hydralazine Hcl | 77 | $1,108 |
| Febuxostat | 17 | $1,082 |
| Clonidine | 15 | $931 |
| Gentamicin Sulfate | 19 | $817 |
| Nifedipine ErNifedipine | 53 | $816 |
| Furosemide | 123 | $651 |
| Amlodipine Besylate | 118 | $567 |
| Metoprolol Succinate | 30 | $520 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga | $1,313 | $81,136113 claims |
| Boehringer IngelheimJardiance | $100 | $73,95995 claims |
| Akebia Therapeutics IncAuryxia | $1,123 | $13,59418 claims |
| ANI Pharmaceuticals, Inc.Valsartan | $52 | $42621 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 206 nephrology providers in Louisiana.
Other nephrology in Baton Rouge
- Jones SamuelBaton Rouge$207K
- Robert LandryBaton Rouge$13K
- Raynold CoronaBaton Rouge$12K
- Damodar KumbalaBaton Rouge$10K
- Kiran PadigalaBaton Rouge$6K
- Christopher LuscyBaton Rouge$6K
- Kenneth SmithBaton Rouge$5K
- James YeggeBaton Rouge$5K
- Mahesh BasireddyBaton Rouge$5K
- William MurrillBaton Rouge$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.